Applications of nanotechnologies for miRNA-based cancer therapeutics: current advances and future perspectives

Frontiers in Bioengineering and Biotechnology, Год журнала: 2023, Номер 11

Опубликована: Июль 27, 2023

MicroRNAs (miRNAs) are short (18-25 nt), non-coding, widely conserved RNA molecules responsible for regulating gene expression via sequence-specific post-transcriptional mechanisms. Since the human miRNA transcriptome regulates of a number tumor suppressors and oncogenes, its dysregulation is associated with clinical onset different types cancer. Despite fact that numerous therapeutic approaches have been designed in recent years to treat cancer, complexity disease manifested by each patient has prevented development highly effective management strategy. However, over past decade, artificial miRNAs (i.e., anti-miRNAs mimics) shown promising results against various cancer types; nevertheless, their targeted delivery could be challenging. Notably, reports nanotechnology-based can greatly contribute hindering initiation processes, representing an innovative disease-modifying strategy Hence, this review, we evaluate recently developed drug systems therapeutics discuss potential challenges future directions, such as use plant-made nanoparticles, phytochemical-mediated modulation miRNAs, nanozymes.

Язык: Английский

---

A new era of cancer immunotherapy: vaccines and miRNAs

Cancer Immunology Immunotherapy, Год журнала: 2025, Номер 74(5)

Опубликована: Апрель 1, 2025

Язык: Английский

---

Hybridization Chain Reaction-Enhanced Ultrasensitive Electrochemical Analysis of miRNAs with a Silver Nano-Reporter on a Gold Nanostructured Electrode Array

Journal of Functional Biomaterials, Год журнала: 2025, Номер 16(3), С. 98 - 98

Опубликована: Март 12, 2025

Abnormal expression of miRNAs is associated with the occurrence and progression cancer other diseases, making essential biomarkers for disease diagnosis prognosis. However, intrinsic properties miRNAs, such as short length, low abundance, high sequence homology, represent great challenges fast accurate miRNA detection in clinics. Herein, we developed a novel hybridization chain reaction (HCR)-based electrochemical chip (e-miRchip), featured gold nanostructured electrodes (GNEs) silver nanoparticle reporters (AgNRs), sensitive multiplexed detection. AgNRs were synthesized applied on e-miRchip to generate strong redox signals presence miRNA. The stem–loop capture probe was covalently immobilized GNEs, opened upon consequently trigger HCR signal amplification. multiple long-repeated DNA helix generated by provides binding sites AgNRs, contributing amplification hybridization. To optimize sensitivity, GNEs three distinct structures electroplated, which flower-like found be best electrode morphology analysis. Under optimal conditions, HCR-based showed an excellent performance LOD 0.9 fM linear range from 1 10 pM. Moreover, this platform able effectively distinguish one- or two-base mismatches. This holds potential highly efficient promising prognosis diseases future.

Язык: Английский

---

Non-coding RNAs as key regulators of epithelial-mesenchymal transition in breast cancer

Frontiers in Cell and Developmental Biology, Год журнала: 2025, Номер 13

Опубликована: Март 25, 2025

This study examines the critical role of non-coding RNAs (ncRNAs) in regulating epithelial-mesenchymal transition (EMT) breast cancer, a prevalent malignancy with significant metastatic potential. EMT, wherein cancer cells acquire mesenchymal traits, is fundamental to metastasis. ncRNAs—such as microRNAs (miRNAs), long (lncRNAs), and circular (circRNAs)—modulate EMT by influencing gene expression signaling pathways, affecting cell migration invasion. review consolidates recent findings on ncRNA-mediated regulation explores their diagnostic therapeutic Specifically, miRNAs inhibit EMT-related transcription factors, while lncRNAs circRNAs regulate through interactions miRNAs, impacting progression. Given influence ncRNAs metastasis resistance, advancing ncRNA-based biomarkers treatments holds promise for improving outcomes.

Язык: Английский

---

MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer

Pathology - Research and Practice, Год журнала: 2023, Номер 248, С. 154618 - 154618

Опубликована: Июнь 13, 2023

Язык: Английский

---

Potential diagnostic and prognostic biomarkers for breast cancer: A compiled review

Pathology - Research and Practice, Год журнала: 2023, Номер 251, С. 154893 - 154893

Опубликована: Окт. 20, 2023

Язык: Английский

---

Sensitive and reliable lab-on-paper biosensor for label-free detection of exosomes by electrochemical impedance spectroscopy

Microchimica Acta, Год журнала: 2024, Номер 191(10)

Опубликована: Сен. 24, 2024

Язык: Английский

---

Determination of Common microRNA Biomarker Candidates in Stage IV Melanoma Patients and a Human Melanoma Cell Line: A Potential Anti-Melanoma Agent Screening Model

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(11), С. 9160 - 9160

Опубликована: Май 23, 2023

MicroRNAs (miRNAs) are small, non-coding RNAs that play an important role in regulating gene expression. Dysregulation of miRNA expression is commonly observed cancer, and it can contribute to malignant cell growth. Melanoma the most fatal type skin neoplasia. Some microRNAs be prospective biomarkers for melanoma stage IV (advanced) at higher risk relapses require validation diagnostic purposes. This work aimed (1) determine significant microRNA biomarker candidates using content analysis scientific literature, (2) show candidates’ efficacy between patients healthy control groups a small-scale preliminary study by blood plasma PCR analysis, (3) markers MelCher human line, which also detected with melanoma, used as drug anti-melanoma activity, (4) test activity humic substances chitosan their ability reduce level marker microRNAs. The literature showed hsa-miR-149-3p, hsa-miR-150-5p, hsa-miR-193a-3p, hsa-miR-21-5p, hsa-miR-155-5p promising diagnosing melanoma. Estimating samples hsa-miR-150-5p may have value (advanced). When comparing ΔCt levels donors, statistically differences were found (p = 0.001 p respectively). Rates significantly among (medians concerning reference miR-320a 1.63 (1.435; 2.975) 6.345 (4.45; 6.98), Therefore, they persist only from group but not donors group. In wild-type (MelCher) culture, presence supernatant was detected. substance fractions tested on cultures, associated activity. It hymatomelanic acid (HMA) fraction its subfraction UPLC-HMA reduced miR-150-5p miR-155-5p ≤ 0.05). For (HA) fraction, this determined Ability cultures molecular weight 10 kDa, 120 or 500 kDa. Anti-melanoma MTT explored substances. median toxic concentration (TC50) HA, HMA (39.3, 39.7 52.0 μg/mL, kDa TC50 much compared (508.9, 6615.9, 11352.3 Thus, our pilot identified testing vitro drugs diagnostics patients. Using gives opportunities new culture has profile similar unlike, example, murine cultures. necessary conduct further studies large number volunteers, will make possible correlate individual specific patient data, including correlation

Язык: Английский

---

Gold nanoparticles attenuate the interferon-γ induced SOCS1 expression and activation of NF-κB p65/50 activity via modulation of microRNA-155-5p in triple-negative breast cancer cells

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Авг. 31, 2023

Triple-negative breast cancer (TNBC) is a very aggressive form of that grows and spreads fast generally relapses. Therapeutic options TNBC are limited still need to be explored completely. Gold nanoparticles conjugated with citrate (citrate-AuNPs) reported have anticancer potential; however, their role in regulating microRNAs (miRNAs) has never been investigated. This study investigated the potential citrate-AuNPs against tumorigenic inflammation via modulation miRNAs cells.Gold were chemically synthesized using trisodium-citrate method characterized by UV-Vis spectrophotometry dynamic light scattering studies. Targetscan bioinformatics was used analyze miRNA target genes. Levels mRNA quantified TaqMan assays. The pairing 3'untranslated region (3'UTR) validated luciferase reporter clone, containing entire 3'UTR mRNA, findings further re-validated transfection inhibitors.Newly highly stable, mean size 28.3 nm. data determined hsa-miR155-5p direct regulator SOCS1 (suppressor-of-cytokine-signaling) expression inhibits mRNA/protein modulating expression. Transfection MDA-MB-231 cells anti-miR155-5p markedly increased (p<0.001), while treatment significantly inhibited transfection-induced (p<0.05). These IFN-γ-stimulated cells. Moreover, also inhibit IFN-γ-induced NF-κB p65/p50 activation transfected anti-hsa-miR155-5p.Newly generated stable non-toxic Citrate-AuNPs deactivate p65/50 activity negative regulation hsa-miR155-5p. novel pharmacological actions on provide insights AuNPs IFN-γ induced microRNAs.

Язык: Английский

---

Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma

International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 8641 - 8660

Опубликована: Авг. 1, 2024

Osteosarcoma is the predominant primary malignant bone tumor that poses a significant global health challenge. MicroRNAs (miRNAs) regulate gene expression are associated with osteosarcoma pathogenesis. Thus, miRNAs potential therapeutic targets for osteosarcoma. Nanoparticles, widely used targeted drug delivery, facilitate miRNA-based treatment. Numerous studies have focused on miRNA delivery using nanoparticles to inhibit progress of Polymer-based, lipid-based, inorganic-based and extracellular vesicles were deliver treatment They can be modified enhance loading capabilities. Also, was combined traditional therapies, example chemotherapy, treat Consequently, offers promising avenues osteosarcoma, providing renewed hope patients. This review emphasizes utilizing in treatment, then introduced summarized detail. And it also discusses prospects clinical applications.

Язык: Английский

---